This is the authors' abstract. We don't add key points for this paper.
The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases Masatomo Ishikawa, Kenji HashimotoDivision of Clinical Neuroscience, Chiba University for Forensic Mental Health, Chiba, JapanAbstract: The endoplasmic reticulum protein sigma-1 receptors, first regarded as opioid receptors and later confused as the phencyclidine (PCP) binding sites of the N-methyl-D-aspartate (NMDA) receptor, are now confirmed to be independent receptors. They are involved in the modulation of various neurotransmitter systems and have a high affinity for diverse classes of psychotropic drugs. Accumulating evidence suggests that the sigma-1 receptors are implicated in higher-ordered brain functions and play important roles in the pathophysiology of neuropsychiatric diseases such as schizophrenia, depression, anxiety disorders, and dementia. Recently, sigma-1 receptors have been shown to function at the molecular level as “receptor chaperones.” This mechanism may unify the explanation of the role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. With the development of the positron emission tomography (PET) ligand [11C]SA4503, it has become possible to visualize sigma-1 receptors and estimate the sigma-1 receptor occupancy of drugs in the human brain. This approach may provide additional information on the function of sigma-1 receptors. This article reviews the function of sigma-1 receptors and attempts to reinterpret their role in the pathophysiology of neuropsychiatric diseases based on their new description as “receptor chaperones.”Keywords: sigma-1 receptor, schizophrenia, major depressive disorder, obsessive-compulsive disorder, Alzheimer’s disease, positron emission tomography
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hashimoto Hashimoto (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: